Scholarlink

Background <p>Hyperlipidemia is a common condition as nearly over 50% of adult Americans have high low-density lipoprotein (LDL) levels. Hyperlipidemia increases the risk of strokes, myocardial infarction, and other vascular events. PCSK9 monoclonal antibodies are one of the available options for the treatment of hyperlipidemia. Our study is a systematic review and meta-analysis that assesses the efficacy and safety of a new PCSK9 antibody, tafolecimab, in hyperlipidemia. </p> Methods <p>Searching PubMed, EMBASE, Scopus, Web of Science (WOS), and Cochrane, we performed a PRISMA-based systematic review and meta-analysis to study effects of tafolecimab compared with placebo on different lipid indices that included LDL percent change, number of patients achieving ≥ 50% low-density lipoprotein cholesterol (LDL-C) reduction, LDL change from baseline, LDL change from baseline (CFB), apolipoprotein B CFB, and non-high-density lipoprotein cholesterol (non-HDL-C) CFB.</p> Results <p>Four randomized controlled trials (RCTs) with 1093 patients were included in our study; 709 (64.87%) of them were males. Tafolecimab reduced LDL percent change [mean difference (MD) = − 62.28, 95% confidence interval (CI) (− 65.21, -59.35), <i>P</i> &lt; 0.00001], the number of patients achieving ≥ 50% LDL-C reduction [MD = 46.92, 95% CI (21.91, 103.9), <i>P</i> &lt; 0.0001], LDL CFB [MD = − 73.58, 95% CI (− 83.13, -64.03), <i>P</i> &lt; 0.001], non-HDL-C CFB [MD = − 82.21, 95% CI (− 86.65, − 77.77), <i>P</i> &lt; 0.001], apolipoprotein B CFB [MD = − 52.01, 95% CI (− 54.86, − 49.17, <i>P</i> &lt; 0.001]. No difference was detected in overall adverse events (AEs) [risk ratio (RR) = 0.94, 95% CI (0.88, 1.01), <i>P</i> = 0.1128], serous AEs [RR = 0.93, 95% CI (0.57, 1.52), <i>P</i> = 0.7799], and AEs leading to treatment discontinuation [RR = 2.58, 95% CI (0.76, 8.77), but yielded more injection site reactions [RR = 2.53, 95% CI (1.14, 5.63), <i>P</i> = 0.0222].</p> Conclusion <p>Tafolecimab is a valuable treatment option for hyperlipidemia, which showed improvement in several lipid indices (LDL, LDL-C, LDL CFB, non-HDL-C CFB, and apolipoprotein B CFB). However, it increased the rates of injection site reactions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of tafolecimab a new PCSK9 inhibitor in patients with hyperlipidemia: a systematic review and meta-analysis of randomized controlled trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Ali Ashraf Salah Ahmed,
  • Ahmad Alkheder,
  • Mohamed Ahmed Ali,
  • Mohamed R. Abdelraouf,
  • Toka Ahmed Ashour,
  • Hazem Mohamed Salamah,
  • Abdelrahman Mahmoud,
  • Diaa Hakim

摘要

Background

Hyperlipidemia is a common condition as nearly over 50% of adult Americans have high low-density lipoprotein (LDL) levels. Hyperlipidemia increases the risk of strokes, myocardial infarction, and other vascular events. PCSK9 monoclonal antibodies are one of the available options for the treatment of hyperlipidemia. Our study is a systematic review and meta-analysis that assesses the efficacy and safety of a new PCSK9 antibody, tafolecimab, in hyperlipidemia.

Methods

Searching PubMed, EMBASE, Scopus, Web of Science (WOS), and Cochrane, we performed a PRISMA-based systematic review and meta-analysis to study effects of tafolecimab compared with placebo on different lipid indices that included LDL percent change, number of patients achieving ≥ 50% low-density lipoprotein cholesterol (LDL-C) reduction, LDL change from baseline, LDL change from baseline (CFB), apolipoprotein B CFB, and non-high-density lipoprotein cholesterol (non-HDL-C) CFB.

Results

Four randomized controlled trials (RCTs) with 1093 patients were included in our study; 709 (64.87%) of them were males. Tafolecimab reduced LDL percent change [mean difference (MD) = − 62.28, 95% confidence interval (CI) (− 65.21, -59.35), P < 0.00001], the number of patients achieving ≥ 50% LDL-C reduction [MD = 46.92, 95% CI (21.91, 103.9), P < 0.0001], LDL CFB [MD = − 73.58, 95% CI (− 83.13, -64.03), P < 0.001], non-HDL-C CFB [MD = − 82.21, 95% CI (− 86.65, − 77.77), P < 0.001], apolipoprotein B CFB [MD = − 52.01, 95% CI (− 54.86, − 49.17, P < 0.001]. No difference was detected in overall adverse events (AEs) [risk ratio (RR) = 0.94, 95% CI (0.88, 1.01), P = 0.1128], serous AEs [RR = 0.93, 95% CI (0.57, 1.52), P = 0.7799], and AEs leading to treatment discontinuation [RR = 2.58, 95% CI (0.76, 8.77), but yielded more injection site reactions [RR = 2.53, 95% CI (1.14, 5.63), P = 0.0222].

Conclusion

Tafolecimab is a valuable treatment option for hyperlipidemia, which showed improvement in several lipid indices (LDL, LDL-C, LDL CFB, non-HDL-C CFB, and apolipoprotein B CFB). However, it increased the rates of injection site reactions.